Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 11, 1998, Pages 2836-2840

  Mégraud, Francis ^a   Occhialini, Alessandra ^a   Rossignol, Jean François ^b  

^a HÔPITAL PELLEGRIN   (France)

^b Romark Institute for Medical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; NITAZOXANIDE; OMEPRAZOLE; THIAZOLE DERIVATIVE; TIZOXANIDE; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CROSS RESISTANCE; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DYSPEPSIA; HELICOBACTER PYLORI; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTIC ULCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STRAIN DIFFERENCE; TREATMENT FAILURE;

EID: 0344734063     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.11.2836     Document Type: Article

References (23)

1. Anonymous. 1997. The report of the Digestive Health Initiative International Update Conference on Helicobacter pylori. Gastroenterology 113:54-58.
2. Bouchard, S., C. Birac, H. Lamouliatte, S. Forestier, and F. Mégraud. 1996. Correlation between the MICs of metronidazole on H. pylori strains and the outcome of a lansoprazole-amoxicillin-metronidazole therapy. Gut 39 (Suppl. 2):A6.
3. Doumbo, O., J. F. Rossignol, E. Pichard, H. Traore, M. M. Dembele, M. Diakite, F. Traore, and A. D. Diallo. 1997. Nitazoxanide in the treatment of cryptosporidiosis in 24 AIDS patients with chronic diarrhea in Mali. Am. J. Trop. Med. Hyg. 56:637-639.
4. Dubreuil, L., X. Houcke, Y. Mouton, and J. F. Rossignol. 1996. In vitro evaluation of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimocrob. Agents Chemother. 40:2266-2270.
5. Glupczynski, Y., L. Boudeaux, C. De Perez, D. Devos, T. Devreker, B. Balegamire, H. Goossens, C. Van den Borre, and J.-P. Butzler. 1991. Prevalence of Helicobacter pylori in rural Kivu, eastern Zaire: a prospective endoscopic study. Eur. J. Gastroenterol. Hepatol. 3:449-455.
6. Glupczynski, Y., and the European Study Group on Antibiotic Susceptibility of H. pylori. 1992. Results of a multicentre European survey in 1991 of metronidazole resistance in H. pylori. Eur. J. Clin. Microbiol. Infect. Dis. 11: 777-781.
7. Goddard, A. F., M. J. Jessa, D. A. Barrett, P. N. Shaw, J. P. Idström, C. Cederberg, and R. C. Spiller. 1996. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 111:358-367.
8. Goodwin, C. S., B. J. Marshall, E. D. Blincow, D. H. Wilson, S. Blackbourn, and M. Philipps. 1988. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J. Clin. Pathol. 41:207-210.
9. Lind, T., S. Veldhuyzen Van Zanten, P. Unge, T. Lind, R. Spiller, E. Bayerdörffer, C. O'Morain, K. Dev Bardhan, M. Bradette, N. Chiba, and M. Wrangstadh. 1996. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the Mach 1 study. Helicobacter 1:138-144.
10. McNulty, C. A. M., J. C. Dent, G. A. Ford, and S. P. Wilkinson. 1988. Inhibitory antimicrobial concentration against Campylobacter pylori in gastric mucosa. J. Antimicrob. Chemother. 22:729-738.
11. Mégraud, F. 1997. Resistance of Helicobacter pylori to antibiotics. Ailment. Pharmacol. Ther. 11(Suppl. 1):43-53.
12. Mégraud, F., and H. P. Doermann. 1998. Clinical relevance of resistant strains of Helicobacter pylori. A review of current data. Gut 43:S61-S65.
13. Mégraud, F., N. Lehn, T. Lind, E. Bayerdörffer, C. O'Morain, R. C. Spiller, P. Unger, S. Veldhuyzen Van Zanten, M. Wrangstadh, and A. Burman. 1997. The MACH 2 study - Helicobacter pylori resistance to antimicrobial agents and its influence on clinical outcome. Gastroenterology 112:A216.
14. Murphy, J., and J. C. Friedman. 1985. Preclinical toxicology of nitazoxanide - a new antiparasitic compound. J. Appl. Toxicol. 5:49-52.
15. Rossignol, J. F., and R. Cavier. 1975. New derivative of 2-benzamido-5-nitrothiazoles. Chem. Abstr. 83:28216n.
16. Shore, P. A., B. B. Brodie, and C. A. M. Hogben. 1957. The gastric secretion of drugs: a pH partition hypothesis. J. Pharmacol. Exp. Ther. 119:361-369.
17. Smith, M. A., and D. I. Edwards. 1995. The influence of microaerophilia and anaerobiosis on metronidazole uptake in Helicobacter pylori. J. Antimicrob. Chemother. 36:453-461.
18. Stockis, A., R. Lins, X. Deroubaix, B. Jeanbaptiste, P. Calderon, and J. F. Rossignol. 1996. Nitazoxanide pharmacokinetics in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 34:349-351.
19. Szybalski, W., and V. Bryson. 1952. Genetic studies on microbial cross resistance to toxic agents. I. Cross resistance of Escherichia coli to fifteen antibiotics. J. Bacteriol. 64:489-499.
20. 19a. Thunus, L. Personal communication.
21. Van der Hulst, R. W. M., J. J. Keller, E. A. J. Rauws, and G. N. J. Tytgat. 1996. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter 1:6-19.
22. Veldhuyzen Van Zanten, S. J. O., J. Goldie, J. Hollingsworth, C. Silletti, H. Richardson, and R. H. Hunt. 1992. Secretion of intravenously administered antibiotics in gastric juice: implications for management of Helicobacter pylori. J. Clin. Pathol. 45:225-227.
23. Wurzer, H., L. Rodrigo, A. Archambault, T. Rokkas, N. Skandalis, R. Fedorak, F. Bazzoli, H. Hentschel, P. Mora, D. Stamler, and F. Mégraud. 1997. Short-course therapy with amoxicillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates H. pylori and heals duodenal ulcer. Aliment. Pharmacol. Ther. 11:943-952.